News
Print
June 2, 2010
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--As disclosed and announced at its 2010 annual general meeting, Advaxis, Inc., (OTCBB: ADXS - News), the live, attenuated Listeria monocytogenes immunotherapy company, and the Science and Technology Directorate division of the Department of Homeland Security (DHS) plan to sign a CRADA (Collaborative Research And Development Agreement) in the next few days that will allow a pilot proof-of-concept cattle safety study to be conducted late this summer.
The DHS will initially conduct a pilot “proof-of-concept” study in cattle investigating the safety of proprietary/patented Advaxis Listeria constructs for use in animals. Oral and injection dosing will be tested.
“This research agreement with the DHS Science and Technology Directorate adds another scientifically respected organization to the existing cooperative research agreements with the National Cancer Institute and Cancer Research UK,” commented Advaxis Chairman/CEO Thomas A. Moore. “These agreements significantly expand the development of our technology at low or no cost to our shareholders.”
About Cooperative Research and Development Agreements
A Cooperative Research and Development Agreement (CRADA) is an agreement between the Federal government and private sector participants to work together on a mutually beneficial project. Each partner in the CRADA applies whatever resources are agreed to, such as personnel, equipment or facilities. While participant dollars may be used to fund portions of the government's effort, the government may not use Federal funds to support the private sector participant.
About the Science and Technology Directorate
The Science and Technology (S&T) Directorate is the primary research and development arm of the Department of Homeland Security. The S&T Directorate's mission is to improve homeland security by providing to customers state-of-the-art technology that helps them achieve their missions. S&T customers include the operating components of the Department, and state, local, tribal and territorial emergency responders and officials. The Directorate has three portfolios that address basic research through advanced technology development and transition - spanning six primary divisions that address critical homeland security needs. For additional information: http://www.dhs.gov/xabout/structure/editorial_0530.shtm
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.
Please visit the Company’s portals: advaxis.com | facebook | twitter |LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contact:
Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
732-545-1084 (FAX)
mir@advaxis.com
or
Advaxis, Incorporated
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
dmoore@advaxis.com
